Novel Biofeedback Device Regulating Arterial Pressure

新型生物反馈调节动脉压装置

• 批准号: 133350
• 金额: $ 13.27万
• 依托单位: CERYX MEDICAL LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=133350
• 关键词: Novel; Biofeedback; Device; Regulating; Arterial

We are developing a novel implantable medical electronic device for drug-free control of Blood Pressure. We are, therefore, addressing a major global health challenge as high Blood Pressure (hypertension) is a major cause of stroke, heart/kidney failure and dementia. 1-in-3 people are hypertensive, the prevalence being highest amongst the older population; with close to 70% of the patients with high Blood Pressure being above the age of 60. Currently, close to 11% of the global population is aged 60 years or over and is estimated to reach nearly 22% by 2050. Our device assists the body to remain healthy by monitoring and controlling biological processes within their normal safe ranges – using a mechanism of biological feedback to attain and track the desired level. The design of our novel device is based on electronic versions of the biological cells normally controlling the function in a healthy body, and like them are analogue (not digital) meaning they respond instantly and use little power. During the project we will optimise the design of the electronics and collect data on the safety, feasibility and efficiency of our device in controlling Blood Pressure.

我们正在开发一种新型的植入式医疗电子设备，用于无药物控制血压。因此，我们正在应对一项重大的全球健康挑战，因为高血压是中风、心脏/肾衰竭和痴呆症的主要原因。三分之一的人患有高血压，在老年人群中患病率最高;近70%的高血压患者年龄在60岁以上。目前，全球近11%的人口年龄在60岁或以上，预计到2050年将达到近22%。我们的设备通过监测和控制正常安全范围内的生物过程来帮助身体保持健康-使用生物反馈机制来达到和跟踪所需的水平。我们的新设备的设计是基于正常控制健康身体功能的生物细胞的电子版本，并且像它们一样是模拟的（而不是数字的），这意味着它们立即做出反应，并且使用很少的功率。在项目期间，我们将优化电子设计，并收集有关我们的设备在控制血压方面的安全性，可行性和效率的数据。